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Transforming Growth Factor b (Tgfb) and associated signaling
effectors are expressed in the forebrain, but little is known about
the role of this multifunctional cytokine during forebrain de-
velopment. Using hippocampal and cortical primary cell cultures of
developing mouse brains, this study identiﬁed Tgfb-regulated genes
not only associated with cell cycle exit of progenitors but also with
adoption of neuronal cell fate. Accordingly, we observed not only
an antimitotic effect of Tgfb on progenitors but also an increased
expression of neuronal markers in Tgfb treated cultures. This effect
was dependent upon Smad4. Furthermore, in vivo loss-of-function
analyses using Tgfb2
2/2/Tgfb3
2/2 double mutant mice showed
the opposite effect of increased cell proliferation and fewer
neurons in the cerebral cortex and hippocampus. Gata2, Runx1, and
Nedd9 were candidate genes regulated by Tgfb and known to be
involved in developmental processes of neuronal progenitors. Using
siRNA-mediated knockdown, we identiﬁed Nedd9 as an essential
signaling component for the Tgfb-dependent increase in neuronal
cell fate. Expression of this scaffolding protein, which is mainly
described as a signaling molecule of the b1-integrin pathway, was
not only induced after Tgfb treatment but was also associated with
morphological changes of the Nestin-positive progenitor pool
observed upon exposure to Tgfb.
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Introduction
Transforming Growth Factor b (Tgfb) isoforms 1, 2, and 3 are
the eponymous members of the Tgfb superfamily that
comprises more than 40 different cytokines. Although several
speciﬁc functions are attributable to each of the isoforms in
vivo, very likely caused by speciﬁc expression of one isoform in
a speciﬁc cellular context, Tgfb1, 2, and 3 are homologous
proteins and probably replaceable in vitro. Thus, for conven-
tion, in this study, we will refer to the term ‘‘Tgfb’’ whenever
exogenous Tgfb was used (normally TGFb1, unless otherwise
indicated) or when we will refer to all 3 isoforms. For in vivo
studies, the speciﬁc isoform used or manipulated is indicated.
Tgfb has versatile functions both between and within
different organ systems. This also holds true for the nervous
system, in which overexpression of Tgfb1 in mice results in
hydrocephalus and gliogenesis (Wyss-Coray et al. 1995),
treatment of dopaminergic neurons with Tgfb causes either
neurotoxic degeneration or neurotrophic effects (Krieglstein
and Unsicker 1994; Krieglstein et al. 1995; Commissiong et al.
1997; Sanchez-Capelo et al. 1999; Farkas et al. 2003), and in
which Tgfb can induce ontogenetic cell death (Krieglstein et al.
2000). Thus, to unravel Tgfb functions in the nervous system, it
is necessary to analyze its actions with respect to different cell
populations and even to different developmental stages. In this
study, we aimed to understand the function of Tgfb during
forebrain development because little is known about the role of
this multifunctional cytokine in this biological context.
Tgfb and corresponding receptors are expressed in the
forebrain: Tgfb2 and Tgfb3 are found in progenitors, differen-
tiating neurons and radial glial cells, whereas Tgfb1i s
expressed mainly in mesenchymal cells of meninges and
choroid plexus during development (Flanders et al. 1991;
Miller 2003; Falk et al. 2008). Tgfb upregulates cell cycle
inhibitors, mainly p21, and counteracts cell cycle progression
of cortical neuroepithelial cells of E10.5 mouse brains and of
E17.5 rat cortical slice cultures (Seoane et al. 2004; Siegenthaler
and Miller 2005). Inactivation of Tgfb receptor II in the
forebrain through Emx1-cre does not alter neuroepithelial
proliferation at E12.5 and lacks a cortical phenotype at E18.5
(Falk et al. 2008). However, Tgfb1 inactivation leads to
a compacted and thinner neocortex accompanied by increased
apoptosis in neonatal and adult mice, indicating that Tgfb1
functions in survival of central nervous system (CNS) neurons
(Brionne et al. 2003).
Further insight into Tgfb function in the CNS comes from
studies of the midbrain, which is also inﬂuenced by Tgfb. Here,
dorsal progenitors are vulnerable to the loss of Wnt1-cre--
induced conditional loss of Tgfb receptor II, leading to
increased cell proliferation and self-renewal of neuroepithelial
cells in vivo and in vitro (Falk et al. 2008). In these animals,
ventral midbrain progenitors are not affected, although ventral
dopaminergic neurons and progenitors respond to Tgfb
signaling. In chicken, Tgfb is involved in differentiation of
a dopaminergic phenotype (Farkas et al. 2003), and Tgfb
neutralization results in selective loss of ventrally located
dopaminergic neurons. Mouse E12.5 ventral midbrain--derived
neurospheres express dopaminergic markers TH and Nurr1
upon exposure to Tgfb. Furthermore, dopaminergic differen-
tiation into a TH- and Nurr1-positive phenotype is also
promoted when dorsal E12.5 midbrain is used for generating
neurospheres (Roussa et al. 2006). In this context of
dopaminergic neuron development, Tgfb increases differenti-
ation but does not inﬂuence proliferation of progenitors
(Roussa et al. 2006).
Several data corroborate the ﬁnding that Tgfb exerts
antimitogenic functions on early neuronal progenitors through
activation of p21, which interferes with G1 progression and
entry into the S phase. Thus, although the idea that Tgfb might
inﬂuence the production of neurons or glial cells from
forebrain progenitors seems likely, it has actually not been
proven so far. And it is conceivable that inhibition of p21 is only
the start, after which further cellular events are initiated and
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forebrain development, we studied the effect of this multi-
functional cytokine on cortical and hippocampal cultures and
on possible target genes. This study shows, for the ﬁrst time,
that Tgfb not only mediates exit from the cell cycle but also
promotes adoption of a neuronal cell fate in vitro and in vivo.
This process is dependent upon Smad signaling and induction
of integrin-signaling protein Nedd9/Hef1.
Materials and Methods
Primary Cultures of Mouse Embryonic Hippocampal and
Cortical Cells
All experiments were performed according to national and interna-
tional guidelines on the ethical use of animals.
Hippocampal and cortical cells were isolated from embryonic mice at
E16.5 or 14.5, dissected in Hanks’ Balanced Salt Solutions (Gibco,
Karlsruhe, Germany) and dissociated by trypsinization in 0.25% Trypsin--
ethylenediaminetetraacetic acid (Gibco) at 37 C for 8 min followed by
gentle trituration. Cells were plated on poly-L-ornithin (0.1 mg/mL,
Sigma, Mu ¨ nchen, Germany) and laminin (1 lg/mL, Sigma) coated dishes
at a density of 150 000 cells/cm
2 and cultured in Neurobasal-medium
(Gibco) supplemented with B27 (Gibco), apo-transferrin (5 lg/mL,
Sigma), glutathione (1 lg/mL, Sigma), superoxide-dismutase (0.8 lg/mL,
Sigma), and glutamine (0.5 mM, Gibco). After 4 days in vitro (DIV), half
of the medium was changed every 3 days.
Immunocytochemistry
Tgfb2/Tgfb3 mutant mice were generated as described (Roussa et al.
2006). Cryosections were processed with microwaving for 7 min twice
in 0.01 M citrate buffer and subsequent blockage of endogenous
peroxidases for Diaminobenzidine (DAB)-based staining. Primary anti-
bodies NeuN (mouse, 1:150, Millipore) and Ki67 (rabbit, 1:100,
Epitomics) were applied overnight and detected with DAB-based
staining (Ki67) or donkey antimouse Cy3 (NeuN). In the latter, red
ﬂuorescence image was converted to black and white using Photoshop.
Only the red channel in the channels palette was activated and inverted
under image-adjustments-invert.
For quantiﬁcation of marker proteins, 0.8 3 10
5 (hippocampus) or
1 3 10
5 (cortex) cells were plated on poly-L-ornithin/laminin precoated
12-mm glass coverslips. For most experiments, TGFb1 (5 ng/mL,
Peprotech, London, United Kingdom) or ALK4,5,7-Inhibitor SB431542
(10 lM, Biozol, Eching, Germany) was added to the medium on DIV2 at
a concentration of 5 ng/mL and replaced with each medium exchange.
TGFb2 and TGFb3 (Peprotech) were used under the same conditions.
Before analysis, cells were ﬁxed in 4% PFA for 10 min, blocked 30 min
in 10% normal goat or donkey serum, 0.1% Triton X-100 in PBS, and
incubated overnight at 4 C with primary antibody in blocking solution,
followed by the corresponding secondary antibody for 1 h at room
temperature in PBS. Primary antibodies used were 5-Bromo-2-
deoxyuridine (BrdU; sheep, 1:500, Abcam), Doublecortin (goat, 1:100,
Santa Cruz Biotechnology), Pax6 (rabbit, 1:300, Covance), Nestin
(rabbit, 1:500, Abcam), GFAP (mouse, 1:500, Sigma), HuC/D (mouse,
1:100, Invitrogen), Ki67 (rat, 1:25, Dako), HEF1 (NEDD9, mouse, 1:500,
Abcam), PSA Ncam (mouse, 1:20, Developmental Studies Hybridoma
Bank), and Smad 1,2,3 (mouse, 1:100, Santa Cruz Biotechnology).
Secondary antibodies used were donkey antimouse, antirabbit, or
antisheep Cy3 (1:800); goat antimouse, antirabbit FITC (1:100); and
donkey antirat FITC (1:100) (all Jackson ImmunoResearch, West Grove,
PA). Cell bodies were counterstained with DAPI (1:1000, Sigma),
coverslips mounted with Fluoromount-G (Southern Biotechnology,
Birmingham, AL) and visualized with an Axio Imager Z1 microscope
(Zeiss, Jena, Germany). Quantiﬁcation was performed by counting 10
random ﬁelds from 2 slides per experimental set. Data were collected
from at least 3 independent experiments and are represented as mean±
standard error of mean (SEM). To verify whether differences between
TGFb1 treatment and untreated control reached the signiﬁcance level
P < 0.05, student’s t-tests were used.
Smad Nuclear Translocation Assay
Hippocampal cells seeded on coverslips were preincubated with
ALK4,5,7-Inhibitor SB431542 (10 lM) for 24 h to suppress endogenous
TGFb signaling. Then, cells were washed twice and stimulated with
TGFb1 (5 ng/mL) for 1 h. After ﬁxation, cells were stained with mouse
anti-Smad 1,2,3 (1:100, Santa Cruz Biotechnology, Santa Cruz, CA).
TGFb Secretion Assay
For detection of active and latent Tgfb released in the culture medium
by cortical and hippocampal cells, the mink lung epithelial cell (MLEC)
luciferase bioassay was used as described (Abe et al. 1994; Krieglstein
et al. 2000).
BrdU Labeling
Cells were plated on coverslips and stimulated with TGFb1 until
ﬁxation at DIV8. Twenty-four hours prior to ﬁxation, 20 nM BrdU
(Sigma) was added to the medium. Fixed cells were incubated in 1 N
HCl for 10 min on ice followed by an incubation for 20 min in 2 N HCl
at 37 C, neutralization in 0.1 M borate buffer and blocking in 5%
normal donkey serum, 1% Triton X-100 in PBS, and incubation with
sheep-anti-BrdU (1:500, Abcam, Cambridge, United Kingdom) over-
night at 4 C. The number of BrdU-positive cells and the total number
of cells were counted. For determination of the quitting fraction (QF),
cells were treated with TGFb1 from DIV2 onward. BrdU was added for
24 h prior to ﬁxation at DIV4. Cells were processed for immunocyto-
chemistry and double labeled with anti-BrdU and anti-Ki67. All BrdU-
positive cells either positive or negative for Ki67 were counted.
FACS Analysis of Apoptotic Cell Death
Hippocampal and cortical cells were treated with 5 ng/mL TGFb1
starting at DIV2. At DIV4 or DIV8, cells were trypsinized, ﬁxed with
70% ethanol in PBS, and stored at –20 C for at least 2 h. Directly before
analysis, DNA was stained with propidium iodide by resuspending the
cells in ﬂuorescence activated cell sorting (FACS) buffer containing 100
lg/mL propidium iodide, 10 lg/mL RNAse in PBS for 30 min at 37 C.
Data are expressed as percentage of cells present in the sub-G1 peak,
representing apoptotic cells.
RNA Isolation and RT-PCR
For Tgfb target gene expression analyses, cells were preincubated with
ALK4,5,7-Inhibitor SB431542 (10 lM) for 24 h to decrease endogenous
Tgfb signaling, washed twice, and stimulated with 5 ng/mL TGFb1 for 2
or 24 h. Expression of Tgfb isoforms and receptors was assessed from
untreated control cells.
Total RNA was isolated at DIV4 or DIV12 using the RNeasy Kit
(Qiagen) according to the manufacturer’s instructions. First-strand cDNA
was synthesized from 1 lg of total RNA with RevertAid MMuLV reverse
transcriptase (Fermentas) using oligo(dT) primers (Invitrogen). One
microliter of the RT reaction mixture was subjected to PCR ampliﬁca-
tion.
Quantitative real-time RT-PCR analysis was performed on an ABI
7500 Real-Time PCR System (Applied Biosystems, Foster City, CA),
using SYBR Green PCR Master Mix (Applied Biosystems) in a MicroAmp
96-well reaction plate following the manufacturer’s protocols. Gapdh
was used as a reference to obtain the relative fold change for target
samples using the comparative CT method. Primer sequences are
shown in supplemental data table S1.
Lentivirus-Delivered RNA Interference
All shRNA containing lentiviral transduction particles were purchased
from Sigma (Mission shRNA). One or 2 constructs for each gene with
more than 85% knockdown efﬁciency were used. For control infection,
nontarget shRNA control was used. Cortical and hippocampal cells
were infected with the viruses at DIV2 for 48 h and then subjected to
selection by 0.8 lg/mL puromycin for 24 h prior to TGFb1 treatment.
Sequences used in the shRNA vectors are shown in supplemental data
table S2.
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Data are presented as the mean ± SEM. Statistical analysis was
performed using 2-tailed unpaired Student’s t-test for in vitro data
and 1-tailed unpaired Student’s t-test for evaluation of in vivo results.
Differences were considered statistically signiﬁcant at *P < 0.05,
**P < 0.01, and ***P < 0.001.
Results
Primary Cortical and Hippocampal Cultures Secrete Tgfb
and Activate Tgfb-Dependent Smad-Signaling Pathways
To determine whether Tgfb signaling is necessary for proper
development of neurons, we used cultures of primary cortical
and hippocampal neurons isolated from E14.5 and E16.5 mouse
embryonic brains. Under the applied cell culture conditions,
primary neurons of both origins produced Tgfb in its active or
inactive, protein-bound latent form over several DIV (Fig. 1A
and data not shown). In vivo studies show that different Tgfb
isoforms are active in speciﬁc parts of the brain during
development, for example, Tgfb1 is mainly produced by
mesenchymal cells of meninges and choroid plexus, whereas
Tgfb2 and Tgfb3 are produced in neural cells (Flanders et al.
1991; Pelton et al. 1991). In vitro, cortical and hippocampal
cells produced all 3 Tgfb isoforms, as well as their main
receptors mediating signal transduction (Fig. 1B). Thus,
primary neuronal cells in culture are endogenously exposed
to Tgfb indicating that this cytokine might play an important
role in neuronal development and function. Furthermore, these
data imply that loss-of-function studies focussing on Tgfb
ligands 1, 2, and 3 would require a knockdown of all 3 isoforms.
To circumvent this difﬁculty, we decided to study Tgfb effects
primarily using exogenous supplementation.
To prove that supply of exogenous Tgfb would result in
the activation of downstream signaling, we analyzed Smad
phosphorylation and translocation into the nucleus. Endog-
enous Tgfb signaling also activated Smad signaling, and this
background activity hampered direct investigation of Smad
phosphorylation and translocation after exongenous supply
of Tgfb. We therefore exposed neuronal cultures for 24 h to
the Alk4,5,7 inhibitor SB431542 to block endogenous Tgfb
signaling and subsequently replaced the inhibitor with 5 ng/
mL TGFb1. Using these conditions, we were able to observe
increased Smad phosphorylation (data not shown) and
translocation (Fig. 1C). Taken together, these data showed
that primary neuronal cultures not only produced all 3 Tgfb
isoforms but also expressed the respective Tgfb receptors
and activated Smad signaling. Expression of all these
different components of Tgfb signal transduction machinery
therefore raised the question whether Tgfb would inﬂuence
cellular processes such as proliferation, apoptosis, or
differentiation.
Tgfb Reduces Progenitor Proliferation and Favors
Differentiation into Neurons
Tgfb signaling is context dependent and involved in diverse
cellular processes affecting different cell populations. Such
cellular processes include proliferation, apoptosis, and differ-
entiation. We therefore analyzed the effect of Tgfb on
embryonal hippocampal and cortical cells with regard to these
cellular processes.
Accordingly, quantitative analyses of the proliferative cell
population in hippocampal cultures after 8 DIV and 6 days of
Tgfb treatment revealed about 12% less Ki67- or BrdU-
positive progenitors compared with untreated cultures
(Fig. 2A). About 7% less Ki67- or BrdU-positive cells were
counted in cortical cultures after Tgfb treatment compared
with untreated control samples (Fig. 2A). This ﬁnding was
corroborated by the observation that Tgfb treatment for 48 h
at DIV2 resulted in a smaller cycling fraction (CF =
(BrdU
+;Ki67
+)/(BrdU
+)) and a higher quitting fraction
(QF = (BrdU
+;Ki67
–)/(BrdU
+)) in hippocampal and cortical
cells (Fig. 2B).
Figure 1. Primary cortical and hippocampal neurons isolated from E14.5 and E16.5
mouse embryonic brains express Tgfbs and their receptors and are responsive to
TGFb treatment. (A) MLEC/PAI--luciferase assay with conditioned medium from DIV4
cortical and hippocampal cultures. Data as mean ± SEM (n 5 3). (B) RT-PCR reveals
that cortical and hippocampal neurons express Tgfb receptors I and II, as well as Tgfb
isoforms 1, 2, and 3. (C) Hippocampal neurons activate Smad proteins upon TGFb
stimulation. Smad1/2/3 immunoreactivity in control untreated cells was localized
diffusely in the cytoplasm, whereas TGFb treatment caused a translocation of Smad
proteins in the nucleus. Upper panels: DIV4, lower panels: DIV12. Scale bars 5 50
lm.
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used propidium iodide--based FACS analyses of Tgfb-treated
samples to test for increased apoptosis that might have led to
a loss of progenitor cells. We did not observe enhanced
apoptosis in hippocampal and cortical cultures that were
exposed either short-term (DIV4) or longer-term (DIV8) to
Tgfb (Fig. 2C). To conﬁrm this ﬁnding, we counted TUNEL-
positive cells and conﬁrmed that Tgfb did not promote cell
death under the applied conditions (data not shown).
Taken together, these observations showed for the ﬁrst time
that exposure to Tgfb resulted in an antiproliferative response
of progenitor cells in hippocampal cultures and corroborated
earlier studies of cortical progenitors.
Because we also determined a higher fraction of cells that
were exiting the cell cycle (Fig. 2B) after Tgfb treatment, we
next investigated whether exposure to Tgfb would result in an
increase of differentiated cells, for example, neurons or glia. We
visualized neurons using HuC/D and NeuN, neural progenitors
using Nestin and Pax6, and glial cells using GFAP (Fig. 3A).
Quantitative analyses revealed that Tgfb treated cultures
contained 17% more neurons in cortical, and 20% more
neurons in hippocampal cultures, but less neuronal progeni-
tors, for example, 12% less Nestin- and 5% less Pax6-expressing
cortical cells, and 9% less Nestin-positive cells in hippocampal
cultures, respectively. The number of GFAP-positive glial cells
was unaffected by Tgfb (Fig. 3B,C).
These experiments were all performed with TGFb1. In vivo,
Tgfb1 is mainly expressed in mesenchymal cells, and Tgfb2 and
Tgfb 3 are active in CNS-derived cells, whereas all 3 isoforms
are expressed in vitro (Fig. 1B). Thus, we also analyzed whether
the observed effect mediated through TGFb1 was also seen
when using the other 2 isoforms. Indeed, we observed that
TGFb2 and TGFb 3 were also capable of increasing the number
of neurons (Fig. 3D).
To investigate whether the length of Tgfb treatment would
be of critical inﬂuence, we exposed cells for 24 h at DIV2 to
Tgfb and analyzed the number of neurons at DIV8. Distribution
of HuC/D-positive neurons indicated that the 24 h Tgfb pulse
was sufﬁcient to increase the number of neurons (Fig. 3E).
Next, we analyzed whether the time point of starting Tgfb
treatment would be important by exposing cultures at DIV5 to
Tgfb for 3 days, and counting HuC/D-positive cells at DIV8.
Under these conditions, we observed only a slight increase in
neurons (7%) (Fig. 3E). We therefore hypothesized that Tgfb is
capable of initiating neuronal differentiation at DIV2 and DIV5
but that the differences observed were due to a shorter time
period during which differentiation would have had time to
progress (6 and 3 days, respectively). Indeed, Tgfb treatment
for 48 h at DIV2 and analysis at DIV4 did not result in more
HuC/D-positive cells, reﬂecting a critical time period that is
necessary for the differentiating neurons to express the
respective markers (data not shown). Cultures treated at
DIV5 for 24 h or 6 days, and analyzed for HuC/D at DIV11,
contained again up to 20% more neurons than untreated cells
(Fig. 3E). Thus, Tgfb was capable of promoting a neuronal cell
fate at DIV2 and DIV5 in similar ratios when cultures were
analyzed after a 6-day differentiation interval. However, Tgfb
treatment produced fewer differentiated neurons in older
cultures treated at DIV8 up to DIV14 (Fig. 3E). This might
reﬂect that older cultures generally contained more neurons
and fewer progenitors under the conditions in B27 medium,
which supports differentiation.
In summary, neuronal progenitors are competent to generate
neurons upon exposure to Tgfb over the entire culture period,
where upon a minimal time frame of 2--3 days is necessary to
detect changes in the expression of differentiation markers.
To further investigate the association of this neurogenic
effect with a functional Tgfb signaling pathway, we treated
cells with Tgfb together with the Alk4,5,7-inhibitor SB431542,
which blocks Tgfb receptor I kinase activity, and observed
a block in the increase in HuC/D positive cells (Fig. 3F). We
next investigated whether the neurogenic effect of Tgfb was
dependent upon Smad signaling, using a lentivirus expressing
a Smad4 shRNA (validation shown in supplementary ﬁg. 1)
that was transduced in cortical and hippocampal cells at DIV2.
We did not observe an increase in neurons after Tgfb
treatment when we interfered with Smad-pathway activity.
Rather, we observed that neurons were generated in similar
numbers as in transduced but non-Tgfb exposed control cells
(Fig. 3G,H), suggesting that Tgfb activation of the Smad-
signaling pathway is a central component of Tgfb-mediated
neuronal differentiation.
Figure 2. TGFb promotes exit from the cell cycle. (A) Hippocampal and cortical cultures were treated for 6 days with TGFb, labeled with BrdU (20 nM) in the last 24 h, and
stained for BrdU and Ki67, detecting decreased numbers of proliferating progenitors (n 5 3), P values: ***P\0.001, **P\0.01, student’s t-test. (B) Determination of cells
leaving the cell cycle within the ﬁrst 48 h of TGFb exposure. Treatment started at DIV2; after 24 h, BrdU was added and after another 24 h, cells were ﬁxed and costained for
BrdU and Ki67. BrdU incorporation had not changed at this time point, but there was an increase in the number of cells quitting the cell cycle (QF) and a corresponding decrease
of cells that reenter the cell cycle (CF) (all n 5 3), P values: ***P\0.001, **P\0.01, student’s t-test. (C) PI-FACS analysis of apoptotic cells after short-time (DIV2--DIV4) and
long-time (DIV2--DIV8) treatment with TGFb (n 5 3).
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not only had antiproliferative functions on hippocampal and
cortical progenitors but also that Tgfb treatment introduced
a bias toward differentiation into neurons, which was
dependent on a functional Tgfb/Smad-signaling pathway.
Tgfb2/Tgfb3 Mutant Mice Display Fewer Neurons and
Increased Progenitor Proliferation
To conﬁrm our ﬁnding that Tgfb signaling interferes with cell
cycle progression and promotes neuronal differentiation in
hippocampal and cortical primary cultures in vivo, we analyzed
Tgfb2
–/–/Tgfb3
–/– double mutant forebrains. Because these
mutations are lethal by E15.5 (Dunker and Krieglstein 2002),
we used E14.5 mutants for analyzing expression of Ki67 and
NeuN. As shown in Figure 4, NeuN staining revealed that a loss
of Tgfb signaling resulted in fewer neurons in the cerebral
cortex (Fig. 4A,B), as well as in the hippocampus (Fig. 4C,D).
The quantiﬁcation of these observations is shown in Figure 4I.
Loss of Tgfb2 and Tgfb3 signaling resulted also in increased cell
proliferation in the cerebral cortex (Fig. 4F) and in the
hippocampus (Fig. 4H) compared with control littermates
Figure 3. TGFb promotes neuronal differentiation from hippocampal and cortical progenitors in a Smad-dependent way. (A) Immunohistochemical appearance of HuC/D and
NeuN expressing neurons, Nestin-positive progenitors, and GFAP-positive glia cells in hippocampal cultures after 6 days of TGFb treatment compared with untreated control cells.
Scale bars 5 50 lm. (B,C) Quantiﬁcation of markers reveals an increase of neurons and a decrease in progenitors in TGFb-treated cultures compared with untreated controls.
The number of glia cells remains unchanged. Data are presented as a percentage of the total cell number. Statistical signiﬁcance was determined by student’s t-test with P
values: ***P\0.001, **P\0.01. (D) Quantiﬁcation of HuC/D-positive neurons after 6-day stimulation of hippocampal cells with Tgfb2 and Tgfb3, respectively, at 8 DIV. (E)
Inﬂuence of the duration of the TGFb pulse and the age of the cultures on the TGFb-induced neurogenetic effect in hippocampal cultures. A short TGFb pulse of 24 h was
sufﬁcient to enhance neuronal differentiation (2,5,7) in the same way as a long pulse of 6 days over the entire cultivation period (1,4,6). TGFb was also able to promote a neuronal
cell fate in older cultures from DIV5 (4,5) at a similar rate as in cultures from DIV2 (1,2). In cultures where TGFb treatment was started on DIV8 (6,7), there was less increase in
the number of HuC/D neurons. Data are presented as percent difference of HuC/D-positive cells of the TGFb-treated cultures based on the untreated controls and given as mean
± SEM (n 5 3). (F) Quantiﬁcation of HuC/D-positive cells under control conditions and after blocking Tgfb signaling with Alk4,5,7 inhibitor SB431542. (G,H) TGFb-mediated
neuronal differentiation was abolished after knockdown of Smad4 by lentiviral transduction of cortical (G) and hippocampal (H) cultures. HuC/D-positive neurons were counted
after transduction with Smad4 shRNA or nontarget shRNA control with and without TGFb treatment (n 5 3).
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corroborated our ﬁndings in primary cell cultures of the
hippocampus and cerebral cortex.
Tgfb-Mediated Neuronal Differentiation is Associated with
Cell Cycle Exit and Induction of Integrin-Associated
Protein Nedd9
Tgfb controls cell cycle progression at the G1/S checkpoint
(Urano et al. 1999; Hu and Zuckerman 2001) and it has been
recognized that Tgfb exerts antiproliferative effects during
cortical development (Siegenthaler and Miller 2005). As
expected, genes associated with cell cycle progression were
also regulated in hippocampal cultures upon exposure to Tgfb.
Speciﬁcally, RT-PCR from cells that were exposed to Tgfb for 2
h revealed that p21 and p57 expression was induced, whereas
a 24-h Tgfb treatment resulted in downregulation of p21, p57,
Ccnd1, and Ccnd2 in E16.5 hippocampal cells cultured for
4DIV (Fig. 5A). The Cdk inhibitors p21 and p57, and the Cdk
activators Ccnd1 and Ccnd2 converge in the regulation of cell
progression through G1 phase and the ratio of p21 to CyclinD--
Cdk complexes determines Cdk activity where high ratios of
Cdk inhibitors to CyclinD--Cdk complexes suppress Cdk
activation and interfere with G1 progression (Sherr 1995).
Thus, induction of p21 and downregulation of Ccnd1 and
Ccnd2 through Tgfb likely prevented neuronal progenitors
from progressing through G1 and entering the S phase.
However, induction of cell cycle inhibitors might be a pre-
requisite for entering differentiation but may not be sufﬁcient
to generate neurons. Because it is unknown whether inhibition
of cell cycle progression is the only function of this
multifunctional cytokine in this context, we examined whether
the neurogenic capacity of Tgfb is associated with the
regulation of further target genes. Several published microarray
data (Verrecchia et al. 2001; Zavadil et al. 2001; Ota et al. 2002;
Kang et al. 2003; Yang et al. 2003; Zhao et al. 2004) identiﬁed
Tgfb-regulated genes in non-CNS-derived cells. We therefore
based our analyses by screening these published data for genes
that might also be relevant for developmental processes of the
forebrain. Altogether, we selected 114 genes (supplementary
Figure 4. Increased proliferation and decreased neuronal differentiation in Tgfb2/Tgfb3 double mutant mice. (A--D) Expression of NeuN in control cortex (A) and hippocampus
(C), and Tgfb2/Tgfb3 double mutant cortex (B) and hippocampus (D) from E14.5 littermates. Scale bar 5 50 lm. (E--H) Expression of Ki67 in control (E) and in Tgfb2/Tgfb3
double mutant cerebral cortex (F), in control (G) and in Tgfb2/Tgfb3 double mutant hippocampus (H). Scale bar E,F 5 50 lm, G,H 5 100 lm. (I, J) Quantiﬁcation of NeuN (I) and
Ki67 (J) positive cells in the cerebral cortex and hippocampus of age-matched control and Tgfb2/Tgfb3 double mutants (n 5 2, P value: * P\0.05, one-tailed student’s t-test).
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campal and cortical cells. Our data showed that hippocampal
and cortical cultures produce Tgfb on their own and thus
exhibit autocrine Tgfb signaling. To circumvent this problem,
we pretreated the cultures with the Alk4,5,7-inhibitor for 24 h
to block endogenous Tgfb signaling and then assessed changes
in expression levels of putative target genes. This was done by
releasing cells from this block and treating hippocampal
cultures for 2 or 24 h with Tgfb at DIV4 (Fig. 5B) and DIV12
(Fig. 5C). Using semiquantitative and quantitative RT PCR, we
identiﬁed Tgfb-regulated target genes associated with neuronal
differentiation of CNS derived progenitors, including Gata2,
Runx1, Nedd9, and Ctgf. These 4 genes were upregulated at
least 3-fold in real-time PCR assays and/or were regulated in
a Smad4-dependent manner (Fig. 5C). Therefore, we investi-
gated whether interference with their expression would also
interfere with Tgfb-associated neuronal cell fate adoption. We
transduced hippocampal cultures with lentiviruses containing
shRNAs for Gata2, Runx1, and Nedd9 (validation shown in
supplementary ﬁg. 2) and investigated hippocampal or cortical
cells that were generated from Ctgf knockout mice (Ivkovic
et al. 2003). As shown in Figure 5D and E, downregulation of
Gata2 and Runx1 did not interfere with Tgfb-mediated
neuronal differentiation. In contrast, downregulation of Nedd9
Figure 5. TGFb-promoted neuronal differentiation depends on the expression of Nedd9.( A) Semiquantitative RT-PCR of cell cycle regulating genes after TGFb stimulation of
hippocampal cultures at 4DIV for 2 and 24 h. (B) Real-time RT-PCR of different Tgfb-regulated genes using cDNA from hippocampal cultures at 4DIV. Given are fold changes after
2 and 24 h of Tgfb treatment, respectively. (C) Real-time RT-PCR of different Tgfb-regulated genes using cDNA from hippocampal cultures at 12DIV. Given are fold changes after
2 and 24 h of Tgfb treatment, respectively. Cells were transduced with a nontarget shRNA control lentivirus or with a Smad4 shRNA lentivirus to assess Smad4-dependent gene
regulation. (D--H) shRNA-mediated knockdown of target genes showed that TGFb-promoted neuronal differentiation was independent of Gata2 (D) and Runx1 (E). No increased
neuronal differentiation was observed in cultures transduced with Nedd9 shRNA lentivirus (F). Cultures of hippocampal or cortical cells from Ctgf mutant mice (
 / ) showed
increased neuronal differentiation after Tgfb treatment in similar ranges as control mice (
þ/þ and
þ/ )( G,H).
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Tgfb (Fig. 5F), indicating that this focal adhesion protein,
known to be involved in integrin signaling, is part of the
molecular machinery that promotes the adoption of a neuronal
cell fate. Loss of Ctgf did not affect the capacity of Tgfb to
generate more neurons in hippocampal or cortical cultures
(Fig. 5G,H).
Tgfb Treatment Alters the Morphology of Nestin-Positive
Progenitors
In the course of our experiments, we observed that Tgfb not
only depleted the pool of neuronal progenitors, but immuno-
cytochemical analyses also revealed that the morphology of this
proliferative pool of cells changed as well (Fig. 6). Nestin is
a marker of multipotential precursors, and Nestin-positive cells
were found in clusters in our cultures. These clusters
contained cells with a large round nucleus and a large cell
body without processes, as well as several cells with a smaller
nucleus and cell body with short processes. Treatment with
Tgfb not only reduced the overall number of Nestin clusters
(data not shown), but it also increased the number of cells with
small cell bodies and processes at the expense of the larger,
rounder cells. In contrast, treatment with the Tgfb-inhibitor
SB431542 favored the larger, rounder phenotype, and small
cells with processes were rarely found (Fig. 6). Costaining with
Ki67 revealed that although Tgfb induced striking morpholog-
ical changes of Nestin-positive progenitors, this subpopulation
of cells still proliferated (Fig. 6A). This ﬁnding suggested that
Figure 6. Morphological changes in Nestin-positive progenitors upon TGFb treatment. (A--E) Preparations of hippocampal cells contain clusters of Nestin-positive progenitors that
have a different morphology in untreated control cultures and also in cultures treated with Alk4,5,7-inhibitor SB431542 compared with TGFb-treated samples.
Immunohistochemical characterization with Nestin and (A) Ki67, (B) GFAP, (C) PSA-NCam, (D) Dcx, and (E) Nedd9. Scale bars 5 50 lm.
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cells. The transition might reﬂect lineage commitment of naive
progenitors that downregulate Nestin and start to express
markers of either the glial or neuronal cell lineages. To
characterize this morphologically distinct cell population, we
used the marker GFAP for glial cells, PSA-NCam for immature
neural precursor cells, and Dcx for precursors of the neuronal
lineage (Fig. 6B,C). A minor fraction of cells displayed
colocalized expression of GFAP and Nestin (Fig. 6B), observable
in Tgfb-treated and control cells, encompassing untreated as
well as Tgfb-inhibitor (SB431542) treated cells. PSA-NCam did
not colocalize with Nestin in control cells, but Tgfb-treated
cells showed partial coexpression (Fig. 6C). No colocalization
with Nestin was found in Dcx-expressing cells under control
and Tgfb-induced conditions (Fig. 6D). These ﬁndings sug-
gested that the Tgfb-induced morphological change did not
correlate with a lineage commitment, but that these cells retain
their uncommitted precursor status.
We identiﬁed Nedd9 as an essential downstream component
of Tgfb-mediated neuronal differentiation. Additionally, Nedd9
has been described as a molecule involved in changes of cell
morphology (Singh et al. 2007), and that is expressed in
multipotent Nestin-positive cells in vivo (Aquino et al. 2008).
We therefore investigated whether the observed Tgfb-
dependent morphological changes correlated with the expres-
sion of Nedd9 in Nestin-positive progenitors. As shown in
Figure 6E, most of the Nestin-positive cells did not express
Nedd9 or expressed Nedd9 only at a low level under both
control conditions. In Tgfb-treated samples, Nestin-positive
cells displayed a higher degree of colocalization with Nedd9,
and nearly all cell bodies of progenitors with Nestin-positive
processes stained positive for Nedd9. Thus, Nedd9 is expressed
in a subset of Nestin-positive cells albeit at a low level, and
exposure to Tgfb induced a higher proportion of Nedd9--Nestin
double-positive progenitors. However, although these ﬁndings
render Nedd9 as a candidate target that might be involved in
the morphological changes of progenitor cells induced by Tgfb,
additional studies with Nedd9 mutant mice will be necessary to
prove this hypothesis.
Discussion
In this study, we have shown that forebrain-derived embryonic
progenitor cells are responsive to Tgfb, which introduces
a shift in differentiation into the neuronal but not into the glial
cell lineage. Thus, Tgfb not only promotes cell cycle exit but
also activates pathways leading to neuronal differentiation,
a process that depends upon the activation of Smad signaling
and the induction of the focal adhesion protein Nedd9.
Our study was focussed on cortical and hippocampal cells
that were cultured in vitro and our ﬁndings extend earlier
reports that Tgfb inﬂuences the developing cerebral cortex.
Using slice cultures of E17.5 rat cerebral cortices, Siegenthaler
and Miller (2005) showed that Tgfb1 promotes cell cycle exit
through induction of p21. We now provide evidence that Tgfb
also inﬂuences hippocampal cells and not only induces exit
from the cell cycle, but that Tgfb also leads to a decrease of
progenitors and increasing numbers of neurons in the de-
veloping hippocampus as well as in the cerebral cortex.
The observed neurogenic potential of Tgfb signaling was
conﬁrmed in vivo using Tgfb2
–/–/Tgfb3
–/– double mutants. This
is the ﬁrst Tgfb-related mouse model in which enhanced cell
proliferation and impaired neuronal differentiation has been
shown in the forebrain.
Tgfb1 knockout mice, which survive to early adulthood,
have a thinner cerebral cortex. This mutant displayed higher
rates of apoptosis in cortical Tgfb1
–/– neurons, which was
considered to be the main cause for loss of neurons (Brionne
et al. 2003). Our data now provide evidence that defects in
neuronal differentiation during development might also have
contributed to the observed loss of neurons. Interestingly,
survival of neurons in our cultures also depended upon Tgfb
signal transduction, because we observed higher rates of
apoptosis when we blocked the TgfbRI with the inhibitor
SB431542 over several days (data not shown).
Other published mouse mutants in which Tgfb signaling is
hampered do not develop an observable phenotype in the
forebrain, as is the case for many TgfbRII conditional mutants
(our own unpublished data, and Falk et al. 2008). In the latter,
one reason for a lack of an observable phenotype might be that
restricting the knockout to a subset of cells using cre-expressing
mice may not have the same effect as a complete knockout of
the 2 major Tgfb ligands that are expressed in neurons and
progenitors (Flanders et al. 1991). Another possibility might be
that loss of Tgfb signaling is accompanied with an increase of
progenitor proliferation. Because neuronal differentiation is not
solely dependent on Tgfb signaling, it might be sufﬁcient if more
precursors are generated, which subsequently differentiate. This
higher number of differentiating precursors might compensate
for the loss of the Tgfb-mediated differentiation signal during the
entire course of development.
Further support for our ﬁnding that Tgfb signaling is
involved in neuronal differentiation comes from studies on
the development of dopaminergic neurons. Here, midbrain-
derived E12.5 progenitors differentiated into dopaminergic
neurons upon exposure to Tgfb in vitro, and this developmen-
tal process was as signiﬁcantly impaired in E14.5 Tgfb2/Tgfb3
double mutants (Roussa et al. 2006).
That Tgfb inﬂuences progenitors not only through cell cycle
exit is corroborated by our observation of morphological
changes of Nestin-positive progenitors. These multipotent cells
nevertheless continue proliferating and do not show any signs
of early lineage restriction after Tgfb treatment. Furthermore,
apart from cell cycle control genes, we identiﬁed other
components that are regulated through Tgfb signaling in
hippocampal and cortical cultures, 4 of which were tested
for their implication in Tgfb-mediated neuronal differentiation.
Although Ctgf, Runx1, and Gata2 are not involved in this
process, siRNA-mediated downregulation of Nedd9 abolished
the neurogenic potential of the Tgfb signaling pathway.
Nedd9 (Neural precursor cell expressed, developmentally
downregulated 9), which was initially identiﬁed in embryonic
brains, is downregulated during developmental progression
(Kumar et al. 1992) and enriched in neural progenitor cells
(Abramova et al. 2005). Further studies identiﬁed Nedd9 in
Nestin- and Sox2-positive progenitors in the neuroepithelium,
and its downregulation is linked to neuronal lineage commit-
ment (Aquino et al. 2008). Furthermore, Nedd9 variation is
associated with susceptibility of late-onset Alzheimer’s disease
and Parkinson’s disease (Chapuis et al. 2008; Li et al. 2008).
Nedd9, also known as Hef1 or Cas-L, is a scaffolding protein
that is implicated in b1-integrin-signal transduction because it
is localized at focal adhesions and associates with focal
adhesion kinase upon b1-integrin ligation. Like Tgfb,i ti s
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attachment, migration, and invasion, as well as apoptosis and
cell cycle regulation (reviewed in Singh et al. 2007). Little is
known about Nedd9 function in the nervous system. Our study
shows for the ﬁrst time that Nedd9 is implicated in Tgfb-
mediated differentiation into the neuronal lineage. Taken
together with its expression pattern, our data suggest that
Nedd9 might promote a progenitor status that renders the cells
competent to differentiation into neurons.
Several studies describe an association of Tgfb-signaling and
Nedd9 activity, although not in the nervous system. In human
dermal ﬁbroblasts, TGFb1 upregulates Nedd9 mRNA and
protein levels but does not change posttranslational modiﬁca-
tions, for example, phosphorylation of Nedd9 (Zheng and
McKeown-Longo 2002). Furthermore, Nedd9 potentiates Tgfb
signaling by relieving negative feedback by the inhibitory
Smads 6 and 7 (Inamoto et al. 2007). Smad3 also interacts with
Nedd9, which can lead to proteasomal degradation of the latter
after Tgfb exposure and therefore facilitates Smad3-mediated
nuclear responses. However, sustained Tgfb signaling leads to
increased levels of Nedd9, which binds Smad3 and negatively
regulates Smad3-dependent Tgfb signaling (Liu et al. 2000;
Nourry et al. 2004). Such pathways might promote differenti-
ation of speciﬁc progenitors as has been shown during spinal
cord development (Garcia-Campmany and Marti 2007) and
might also take place during forebrain development.
Taken together, our data provide new ﬁndings on the role of
Tgfb on hippocampal as well as cortical cells and highlight
a role for Nedd9 in neuronal differentiation. These data will be
the basis for extended studies to enlighten the function of
Nedd9 in different CNS-derived progenitor populations and
with respect to different developmental time points.
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